Cargando…
New Marine Derived Anticancer Therapeutics ─ A Journey from the Sea to Clinical Trials
Nature has been instrumental as a source for therapeutics. Despite the fact that we live in an oceanic planet, a number of technical factors have historically hampered the evolution of a marine-based chamanic medicine. With the implementation of scuba diving tools and the development of sophisticate...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Molecular Diversity Preservation International (MDPI)
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3783878/ |
_version_ | 1782285737358524416 |
---|---|
author | Jimeno, J. Faircloth, G. Sousa-Faro, JM Fernández Scheuer, P. Rinehart, K. |
author_facet | Jimeno, J. Faircloth, G. Sousa-Faro, JM Fernández Scheuer, P. Rinehart, K. |
author_sort | Jimeno, J. |
collection | PubMed |
description | Nature has been instrumental as a source for therapeutics. Despite the fact that we live in an oceanic planet, a number of technical factors have historically hampered the evolution of a marine-based chamanic medicine. With the implementation of scuba diving tools and the development of sophisticated instruments for the isolation and elucidation of structures of natural products from marine organisms, major advances have been made in the discovery of marine derived therapeutics. The availability of ARA-C, a nucleoside analog that is a basic component in the treatment of acute myeloid leukemia, and its fluorinated analog Gemcitabine, an important therapeutic tool in the treatment of pancreatic cancer and in non small cell lung cancer, is a solid proof and validation of the potential of this approach. As a result of our discovery and developmental program, three innovative compounds with novel mechanisms of action: ET-743, Aplidin(R) and Kahalalide F, have been shown to display a positive therapeutic index and activity in resistant solid tumors that supports the ongoing clinical phase III/II trials. ET-743 represents the first active agent against sarcomas developed in the past 25 years and has demonstrated a therapeutic potential in pretreated ovarian cancer. Several chemical entities are under advanced preclinical testing and additional candidates for clinical development are emerging, including compounds hitting a specific target. Moreover, the development of a given marine candidate implies the collaboration of an interdisciplinary team special focused on supply, formulation, pharmacogenetics and preclinical toxicology. |
format | Online Article Text |
id | pubmed-3783878 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2004 |
publisher | Molecular Diversity Preservation International (MDPI) |
record_format | MEDLINE/PubMed |
spelling | pubmed-37838782013-10-17 New Marine Derived Anticancer Therapeutics ─ A Journey from the Sea to Clinical Trials Jimeno, J. Faircloth, G. Sousa-Faro, JM Fernández Scheuer, P. Rinehart, K. Mar Drugs Review Nature has been instrumental as a source for therapeutics. Despite the fact that we live in an oceanic planet, a number of technical factors have historically hampered the evolution of a marine-based chamanic medicine. With the implementation of scuba diving tools and the development of sophisticated instruments for the isolation and elucidation of structures of natural products from marine organisms, major advances have been made in the discovery of marine derived therapeutics. The availability of ARA-C, a nucleoside analog that is a basic component in the treatment of acute myeloid leukemia, and its fluorinated analog Gemcitabine, an important therapeutic tool in the treatment of pancreatic cancer and in non small cell lung cancer, is a solid proof and validation of the potential of this approach. As a result of our discovery and developmental program, three innovative compounds with novel mechanisms of action: ET-743, Aplidin(R) and Kahalalide F, have been shown to display a positive therapeutic index and activity in resistant solid tumors that supports the ongoing clinical phase III/II trials. ET-743 represents the first active agent against sarcomas developed in the past 25 years and has demonstrated a therapeutic potential in pretreated ovarian cancer. Several chemical entities are under advanced preclinical testing and additional candidates for clinical development are emerging, including compounds hitting a specific target. Moreover, the development of a given marine candidate implies the collaboration of an interdisciplinary team special focused on supply, formulation, pharmacogenetics and preclinical toxicology. Molecular Diversity Preservation International (MDPI) 2004-02-25 /pmc/articles/PMC3783878/ Text en © 2004 by MDPI Reproduction is permitted for noncommercial purposes. |
spellingShingle | Review Jimeno, J. Faircloth, G. Sousa-Faro, JM Fernández Scheuer, P. Rinehart, K. New Marine Derived Anticancer Therapeutics ─ A Journey from the Sea to Clinical Trials |
title | New Marine Derived Anticancer Therapeutics ─ A Journey from the Sea to Clinical Trials |
title_full | New Marine Derived Anticancer Therapeutics ─ A Journey from the Sea to Clinical Trials |
title_fullStr | New Marine Derived Anticancer Therapeutics ─ A Journey from the Sea to Clinical Trials |
title_full_unstemmed | New Marine Derived Anticancer Therapeutics ─ A Journey from the Sea to Clinical Trials |
title_short | New Marine Derived Anticancer Therapeutics ─ A Journey from the Sea to Clinical Trials |
title_sort | new marine derived anticancer therapeutics ─ a journey from the sea to clinical trials |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3783878/ |
work_keys_str_mv | AT jimenoj newmarinederivedanticancertherapeuticsajourneyfromtheseatoclinicaltrials AT fairclothg newmarinederivedanticancertherapeuticsajourneyfromtheseatoclinicaltrials AT sousafarojmfernandez newmarinederivedanticancertherapeuticsajourneyfromtheseatoclinicaltrials AT scheuerp newmarinederivedanticancertherapeuticsajourneyfromtheseatoclinicaltrials AT rinehartk newmarinederivedanticancertherapeuticsajourneyfromtheseatoclinicaltrials |